Charles Schwab Investment Management Inc. Has $5.75 Million Stake in Anavex Life Sciences Corp. $AVXL

Charles Schwab Investment Management Inc. lowered its stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 1.1% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 669,911 shares of the biotechnology company’s stock after selling 7,304 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.78% of Anavex Life Sciences worth $5,748,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in AVXL. LPL Financial LLC boosted its stake in Anavex Life Sciences by 482.1% during the 1st quarter. LPL Financial LLC now owns 546,626 shares of the biotechnology company’s stock valued at $4,690,000 after purchasing an additional 452,723 shares during the last quarter. Vanguard Group Inc. boosted its stake in Anavex Life Sciences by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 4,902,246 shares of the biotechnology company’s stock valued at $42,061,000 after purchasing an additional 221,802 shares during the last quarter. Private Advisor Group LLC boosted its stake in Anavex Life Sciences by 617.5% during the 1st quarter. Private Advisor Group LLC now owns 214,725 shares of the biotechnology company’s stock valued at $1,842,000 after purchasing an additional 184,800 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in Anavex Life Sciences by 197.7% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 248,139 shares of the biotechnology company’s stock valued at $2,129,000 after purchasing an additional 164,792 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in Anavex Life Sciences during the 4th quarter valued at about $1,704,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Trading Down 0.8%

NASDAQ:AVXL opened at $9.45 on Thursday. The stock has a market capitalization of $811.66 million, a PE ratio of -16.58 and a beta of 0.80. The firm’s 50 day moving average is $10.52 and its 200 day moving average is $9.24. Anavex Life Sciences Corp. has a 12 month low of $4.93 and a 12 month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Research analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Ratings Changes

AVXL has been the subject of a number of analyst reports. D. Boral Capital reiterated a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research note on Wednesday. Wall Street Zen downgraded Anavex Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a research note on Friday, August 22nd. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $44.00.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.